Metoclopramida Kern Pharma

Metoclopramide, the active ingredient in Metoclopramida Kern Pharma, is a dopamine antagonist presented as an injectable solution for intramuscular and intravenous use. It treats nausea, vomiting and gastroparesis in adult patients. GNH USA supplies Metoclopramida Kern Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramida Kern Pharma acts on the dopaminergic pathways that trigger nausea and impair gastric motility. - Nausea and vomiting: provides relief by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric emptying through increased acetylcholine release. - Migraine-associated nausea: reduces nausea symptoms that accompany migraine attacks.

Metoclopramida Kern Pharma may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or akathisia - Diarrhea - Headache - Dry mouth

Serious or Rare Side Effects: - Extrapyramidal symptoms, including dystonia - Tardive dyskinesia with long‑term use - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Anaphylactic reaction - Cardiac arrhythmias (rare)

Metoclopramida Kern Pharma requires careful consideration of patient‑specific factors before use. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider potential infant exposure. - Renal impairment: dose adjustment may be necessary. - Elderly: increased sensitivity to central nervous system effects. - Concomitant CNS depressants: monitor for enhanced sedation. Store below 25°C: keep in original container, protect from light and moisture.

Metoclopramida Kern Pharma can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Anticholinergic agents: may diminish prokinetic effect. - CYP2D6 inhibitors (e.g., fluoxetine): increase plasma concentrations. - MAO inhibitors: risk of hypertensive crisis. - Other dopamine antagonists: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - CNS depressants (opioids, benzodiazepines): enhanced sedation. - Selective serotonin reuptake inhibitors: rare risk of serotonin syndrome. - Loop diuretics: may exacerbate electrolyte disturbances.